Ovid Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
OVID$2.850.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| (in thousands) | For the Year Ended December 31, 2025 | For the Year Ended December 31, 2024 |
|---|---|---|
| Net loss | $(17,414) | $(26,433) |
| Other comprehensive (loss) income: | ||
| Cumulative translation adjustment | (140) | (42) |
| Unrealized (loss) gain on available-for-sale securities | (27) | 7 |
| Comprehensive loss | $(17,581) | $(26,468) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.